|
Clinical effectiveness of Helicobacter pylori eradication in gastric cancer survivors after endoscopic resection of early gastric cancer was recently established in a randomized controlled trial.
Dr Dong Wook Shin and colleagues from Korea established long-term cost-effectiveness in gastric cancer survivors after endoscopic resection of early gastric cancer.
The team constructed a Markov model to compare the costs and outcomes of the 2 intervention strategies.
The first invtervention strategy included eradicating H pylori after complete resection of early gastric cancer by endoscopy.
 |
| H pylori eradication costs less at US$ 29,780 |
| Helicobacter |
The team's second strategy was not to eradicate.
Estimates for variables in the model were obtained by extensive review of published reports.
Analyses were made from the Korean public healthcare provider's perspective.
The researchers found that H pylori eradication costs less at US$ 29,780 than no eradication at US$ 30,594, and saves more lives.
The team applied sensitivity analyses to show the robustness of the cost-effectiveness results.
Dr Shin's team concluded, "In this selective population with very high risk of developing gastric cancer, H pylori eradication should be considered for reimbursement with priority to prevent subsequent cancer and also reduce health care cost."
| 
Email this page to a colleague
